Recruiting Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer NCT06900595 Conditions Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +16 more Locations UC San Diego Moores Cancer Center — La Jolla, California, United States Valley Children's Hospital — Madera, California, United States UCHealth University of Colorado Hospital — Aurora, Colorado, United States Lurie Children's Hospital-Chicago — Chicago, Illinois, United States View all 77 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors NCT02867592 Conditions Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more Locations Children's Hospital of Alabama — Birmingham, Alabama, United States Providence Alaska Medical Center — Anchorage, Alaska, United States Arkansas Children's Hospital — Little Rock, Arkansas, United States Kaiser Permanente-Anaheim — Anaheim, California, United States View all 142 locations View more locations Show fewer locations Loading locations... View Trial Details
